Fertigyn HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for medical use in fertility and endocrine disorders. It is engineered to deliver consistent biological activity, supporting ovulation induction, spermatogenesis, and testosterone production with high reliability. This product is intended for use under strict medical supervision, ensuring optimal therapeutic outcomes in controlled clinical settings.

Features

• Contains highly purified human chorionic gonadotropin (hCG)
• Available in lyophilized powder form for reconstitution
• Precisely calibrated international units (IU) per vial
• Manufactured under stringent quality control standards
• Compatible with standard sterile diluents
• Packaged with detailed prescribing information

Benefits

• Supports successful ovulation induction in anovulatory women
• Aids in the development of viable sperm in male hypogonadism
• Helps stimulate testosterone production in cases of hypogonadotropic hypogonadism
• Provides predictable and consistent hormonal activity
• Enables tailored dosing under medical guidance
• Facilitates improved treatment outcomes in assisted reproductive technologies

Common use

Fertigyn HP is commonly used in reproductive medicine for the treatment of infertility in both women and men. In female patients, it is indicated for the induction of ovulation in cases of anovulation or oligo-ovulation, particularly following preliminary follicular growth stimulation with other agents. In male patients, it is used to stimulate spermatogenesis and support testosterone production in those with hypogonadotropic hypogonadism. It may also be employed in prepubertal cryptorchidism under specific circumstances.

Dosage and direction

Dosage must be individualized based on the patient’s condition, response, and treatment protocol. Typically administered via intramuscular injection after reconstitution with the provided solvent.

• For ovulation induction: 5,000–10,000 IU administered once, usually following follicle maturation.
• For male hypogonadism: 1,000–4,000 IU administered 2–3 times per week for several months.
  Reconstitute immediately before use; swirl gently—do not shake—to avoid denaturation. Use aseptic technique. Dispose of any unused solution appropriately.

Precautions

• Use only under supervision of a healthcare provider experienced in fertility treatments.
• Monitor for ovarian hyperstimulation syndrome (OHSS) in female patients; discontinue if suspected.
• Regular ultrasounds and hormone level assessments are recommended during treatment.
• Use with caution in patients with asthma, epilepsy, migraine, or renal or cardiac impairment.
• May cause fluid retention; advise patients to report sudden weight gain, edema, or shortness of breath.
• Not recommended for use in patients with hormone-dependent malignancies.

Contraindications

• Hypersensitivity to hCG or any component of the formulation.
• Prior allergic reaction to any gonadotropin preparation.
• Ovarian cyst or enlargement not due to polycystic ovary syndrome.
• Uncontrolled thyroid or adrenal dysfunction.
• Pituitary gland tumors.
• Abnormal uterine bleeding of undetermined origin.
• Prostate cancer or other androgen-dependent neoplasms in males.

Possible side effect

Common side effects may include:

• Headache
• Irritability
• Restlessness
• Fatigue
• Edema
• Mild injection site reactions (pain, redness, swelling)

Less frequently, patients may experience:

• Ovarian hyperstimulation syndrome (OHSS)
• Gynecomastia in males
• Early puberty in pediatric use
• Thromboembolic events (rare)

Report any severe or persistent symptoms to a healthcare provider immediately.

Drug interaction

• May interact with other gonadotropins or fertility medications, potentially increasing the risk of OHSS.
• Concurrent use with corticosteroids may amplify androgenic effects.
• Not recommended with other hormonal therapies unless directed by a specialist.
• Inform your physician of all current medications, including over-the-counter drugs and supplements.

Missed dose

If a dose is missed, administer it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consult the prescribing physician for specific guidance based on the treatment protocol.

Overdose

Overdose may lead to exaggerated side effects, such as severe OHSS in women (characterized by abdominal pain, nausea, vomiting, ovarian enlargement, ascites) or excessive androgen effects in men (including aggressive behavior, acne, excessive hair growth). In case of suspected overdose, discontinue use immediately and seek urgent medical attention. Supportive and symptomatic treatment is advised.

Storage

Store in a refrigerator between 2°C and 8°C (36°F–46°F). Do not freeze. Protect from light. After reconstitution, use immediately—do not store. Keep out of reach of children and pets. Discard any unused product appropriately according to medical waste guidelines.

Disclaimer

This information is intended for medical professionals and educated patients under medical supervision. It is not exhaustive and does not replace professional medical advice, diagnosis, or treatment. Always follow the specific instructions provided by the prescribing healthcare provider. The manufacturer is not liable for misuse or incorrect administration.

Reviews

Clinical studies and expert reviews highlight Fertigyn HP as an effective and reliable hCG product when used according to established protocols. Physicians report satisfactory outcomes in ovulation induction and male hypogonadism treatment, noting its consistency and purity. Patient experiences vary based on individual factors; adherence to medical guidance is critical for success.